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The co-ordinated synthesis and degradation of the extracellular
matrix (ECM) maintains structural organization of connective
tissues. ECM degradation by proteinases is involved in both
physiological, e.g. wound healing and bone remodelling, and
pathological processes, e.g. cancer and arthritis. The difference in
ECM degradation in these processes is that it is normally tightly
regulated and the normal matrix boundaries are preserved (Khokha
et al, 1995). However, in pathological processes, such as tumour
invasion and metastasis, ECM turnover is not regulated normally
resulting in loss of matrix function and compromised matrix
boundaries (Cocoran et al, 1996). The proteinases involved in
tissue degradation are subject to strict regulatory mechanisms
including their synthesis, secretion, catalytic activity and the exis-
tence of specific natural proteinase inhibitors (Testa and Quigley,
1990). In cancer, proteinases are thought to enhance cancer
invasion by catalysing the degradation of ECM components. Such
degradation occurs at several stages of the metastatic cascade,
including angiogenesis, local invasion and intravasation. Since
multiple ECM components exist, a number of different proteinases
are likely to be required to complete the metastatic sequence. These
proteinases can be subdivided into four distinct sub-classes based
on their catalytic mechanism: serine, cysteine, aspartic and matrix
metalloproteinases (MMPs) (Barrett, 1995). The proteinases
primarily involved in ECM degradation in tumour invasion and
metastasis are the MMPs and plasminogen activators.
MMPs or matrixins, are a family of zinc- and calcium-depen-
dent endopeptidases that have the combined ability to break down
all ECM components. Fourteen human MMPs exist and these can
be grouped according to their domain structure into at least five
groups: the collagenases, gelatinases, stromelysins, membrane-
type MMPs and others (Baramova and Foidart, 1995). MMPs can
exist in latent and active forms and complexed with and without
their specific inhibitors, the tissue inhibitors of metalloproteinases
(TIMPs). MMP activity is regulated at several levels, including
gene expression, secretion, activation and inhibition by the
TIMPs. Four human TIMPs have been identified to date (TIMPs
1–4) which have closely related structures and inhibitory proper-
ties. TIMPs bind non-covalently to active MMPs forming essen-
tially irreversible complexes inhibiting MMP activity (Cawston et
al, 1983). Certain TIMPs also bind to latent forms of MMPs, e.g.
TIMP-1 to latent MMP-9 and TIMP-2 to latent MMP-2, thus
controlling the activation of these latent MMPs. It is therefore the
balance between the levels of activated MMPs and free TIMPs
that determines the overall MMP activity and ECM degradation.
Plasminogen activators (PAs) are members of the serine proteinase
family and two PAs exist, urokinase-type (uPA) and tissue type (tPA).
PAs cleave plasminogen to the active proteinase plasmin, which can
catalyse the degradation of a variety of proteins including fibrin and
laminin (Kwaan, 1992), as well as activating other proteinases by
cleaving the pro-form, e.g. MMP-1 (interstitial collagenase). The
catalytic activity of this plasminogen–plasmin system is modulated
by PAs and by inhibitors of both plasmin and PAs. Plasmin inhibitors
include a-2 antiplasmin and a-2-macroglobulin, and PA inhibitors
include the type 1 and 2 plasminogen activator inhibitors (PAIs).
Proteinase expression has been extensively studied in many
different human cancers including breast (Schmitt et al, 1991;
Clavel et al, 1992; Brown et al, 1993; Davies et al, 1993; Duffy et
al, 1993; Remacle et al, 1998), colorectal (Hewitt et al, 1991;
Liabakk et al, 1996; Parsons et al, 1998), prostate (Hamdy et al,
1994) and stomach (Torii et al, 1997). These studies used a variety
of techniques, including immunohistochemistry, zymography and
enzyme-linked immunosorbent assays (ELISAs); however, no
previous study has compared the factors involved in proteolysis in
different cancers, or used a variety of techniques to do so.
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tumours and the surrounding ECM may vary in different tissues.
Therefore different proteinases may be involved for successful
invasion and metastasis in different human tumours. The aim of
the current study was therefore to compare the process of proteo-
lysis in two human cancers, breast and colorectal cancer. To
determine whether there were differences in proteolysis in these
cancers, three different techniques were employed and these
determined three different aspects of proteolysis. First, substrate
zymography determined the expression of different proteinases
(MMPs and PAs) in paired tumour and normal tissue samples from
patients undergoing surgical resection for breast and colorectal
cancer. Secondly, Western blotting compared the expression of
inhibitors (TIMP-1 and -2) in the same samples and finally
quenched fluorescence substrate hydrolysis determined total ‘free’
MMP activity and therefore potential ECM degradation of each
tissue sample.
MATERIALS AND METHODS
Tissue samples
Paired fresh tumour and normal breast (n = 43) and colorectal
(n = 24) tissue samples were collected in RPMI media by a consul-
tant histopathologist from Histopathology Department, Royal
Hallamshire Hospital, Sheffield after surgical resection for breast
and colorectal cancer. The tissue samples were mechanically
disaggregated using scalpel blades and graded needles, to yield a
single cell suspension. The cell suspension was centrifuged at
2100 rpm for 10 min. The cell pellet was resuspended and the
viable cells were counted using a haemocytometer (Neubauer,
Phillip Harris Scientific). After counting, the cell pellet was
reformed and the cells resuspended in lysis buffer (0.1% Triton
X-100 in 0.05 M trizma base, 0.2 M sodium chloride (NaCl) and
0.005 M calcium chloride (CaCl2) at a concentration of 10 ´ 106
cells per ml buffer.
Zymography
Before substrate zymography, the tissue sample lysates were
mixed 3:1 with non-reducing sample buffer (0.5 M Tris–HCI,
pH 6.8, sodium dodecyl sulphate (SDS), glycerol and
bromophenol blue).
Gelatin zymography
Gelatin zymography was performed to determine the expression of
gelatinase A (MMP-2) and gelatinase B (MMP-9) in the different
tissue samples (Heussen and Dowdle, 1980). Each sample (20 ml)
was run in parallel with a molecular weight marker and MMP-2
and MMP-9 protein standards (where available, TCS Biologicals,
UK) on SDS-polyacrylamide gels (7.5%) containing 0.1% gelatin
as the substrate. Gels were electrophoresed at 200 V for 1 h (mini-
V 8.10; BRL Life Technologies, UK). After electrophoresis, the
gel was washed in 2% Triton X-100 for 1 h at room temperature on
an orbital shaker. The substrate gel was then incubated overnight
with MMP incubation buffer (0.05 M trizma base, 0.2 M NaCl,
5m M CaCl2). Following incubation, gels were stained with 0.2%
solution Coomassie blue for 15 min and then destained (10%
acetic acid and 30% methanol) for 10 min. Proteolytic activity
was represented by clear lysis bands of degraded protein on a
uniformly blue background.
Casein zymography
The presence of stromelysin-1 (MMP-3) was determined using a
12% SDS-polyacrylamide substrate gel containing 0.1% casein
(Seftor, 1994).
Collagen I zymography
The presence of interstitial collagenase (MMP-1) was determined
using a substrate gel containing 0.1% collagen type I in 12% SDS-
polyacrylamide gel.
Control gels for MMPs
Control gels contained either of the MMP inhibitors, EDTA or
1,10 phenanthroline in the MMP incubation buffer to confirm that
the lysis bands were due to MMPs.
Double substrate zymography
Double substrate zymography was used to determine the presence
of PAs in tissue samples (Seftor, 1994). The two substrates used
were plasminogen (substrate 1) and gelatin (substrate 2). The plas-
minogen acts as a substrate for any PAs present in the sample, by
cleaving plasminogen to the active enzyme, plasmin, which subse-
quently degrades the gelatin. The PA incubation buffer (0.25 M
trizma base, pH 8.1) contained EDTA to eliminate any gelatinase
activity in the sample on the substrate gelatin.
Control gels for PAs
Each sample was also run down two control gels, the first gel only
contained gelatin as a substrate, therefore any PAs present in the
samples would be unable to degrade the gelatin, and the second gel
contained the serine proteinase inhibitor phenylmethylsulphonyl
fluoride in the incubation buffer to determine if lysis bands were
due to PAs.
Quantitation of the gels
Gels were quantitated using laser densitometry. Gels were scanned
and analysed using the Quantity One software (Discovery Series,
Pharmacia Biotech, UK). The image of the gel was inverted to
reveal dark bands on a white background. The molecular weight,
area and optical density of each band were determined. The rela-
tive proteinase activity was determined for each proteinase by
multiplying the area of each band by its optical density.
Western blotting
Western blotting was performed on the same breast and colorectal
tissue samples to determine the expression of the TIMPs, TIMP-1
and TIMP-2. Samples were run down SDS polyacrylamide gels
(15%) and electrophoresed at 200 V for 1 h. Control TIMP proteins
(TIMP-1 and TIMP-2; Calbiochem, UK) were run in parallel with
tissue samples. Proteins within the gel were then blotted onto a
nitrocellulose membrane following electrophoresis at 150 V for
1 h. Once protein transfer was completed the membrane was incu-
bated with blocking agent for 1 h to stop any non-specific binding.
After washing, the membrane was incubated with the primary anti-
body (TIMP-1 or TIMP-2 mouse anti-human antibodies; 1 mg ml–1
TIMP-1 or 5 mg ml–1 TIMP-2; Calbiochem UK), for 1 h. It was then
rinsed and incubated with the secondary antibody (anti-mouse
peroxidase labelled secondary antibody) for 1 h.
Detection and analysis
The membranes were washed and drained and the detection
reagent added to the protein side of the membrane for 1 min.
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protein side down onto a piece of Sarawrap (plastic tool wrap).
The membrane was then exposed to an autoradiography film and
the film was developed. The protein bands on the processed film
were analysed by densitometry.
Quenched fluorescence substrate hydrolysis
The technique of quenched fluorescence substrate hydrolysis
employs the quenched fluorescence substrate Mca-Pro-Leu-Gly-
Leu-Dpa-Ala-Arg-NH2 which is cleaved by all secreted activated
MMPs, so far tested (Brown et al, 1996), at the Gly-Leu bond
releasing the fluorescent Mca group from the internal quenching
group Dpa (Knight et al, 1992). The total MMP activity was deter-
mined in all tissue samples by incubating 150-ml tissue sample
lysate with 2835-ml assay buffer (0.1 M Tris–HCl, 0.1 M NaCl,
10 mM CaCl2, pH 7.5) and 15 ml of the fluorescent substrate
(5  mM). The samples were incubated for 3 h at 37°C and the MMP
activity was determined on a fluorimeter (Perkin-Elmer LS50B)
(lex 328 nm and lem 393 nm) running the FLDM software. A total
of 150 ml lysis buffer incubated as above acted as the negative
control.
The fluorimeter was standardized (maximum fluorescence was set
by the addition of 0.5-mM standard, Mca-Pro-Leu-OH, the fluores-
cent product produced) so that a comparative rate of substrate
hydrolysis was determined for each sample and expressed as pM
min–1.
Statistical analysis
For comparisons between proteinase and inhibitor expression in
breast and colorectal, tumour and normal tissue samples, the
Mann–Whitney U-test for non-parametric data, with 95% confi-
dence limits was performed. Differences were considered to be
significant at P < 0.05 level.
RESULTS
There was a wide variation in the proportion of breast and
colorectal samples expressing each proteinase and inhibitor (Table
1) as well as the amount of each protein expressed (Table 2).
Proteinase expression by substrate zymography
Colorectal and breast tissues, as well as tumour and normal tissue
samples exhibited differential proteinase profiles. After zymog-
raphy, the number of samples expressing each MMP lysis band
were determined by running the relevant MMP control protein in
parallel down the substrate zymogram. In both tissue types, the
greatest difference in proteinase expression was observed after
gelatin zymography.
MMP-2 and MMP-9 expression
Gelatin zymography identifies and separates the gelatinases MMP-
2 and MMP-9 in both latent and active forms due to differences
in their molecular mass. In both breast and colorectal tissue the
following four lysis bands were observed in the samples: 92 kDa
corresponding to latent MMP-9; 84 kDa active MMP-9; 72 kDa
latent MMP-2, and finally 68 kDa active MMP-2.
Latent MMP-2 and latent MMP-9 expression was observed in a
similar proportion of tumour and normal tissue samples in both
breast and colorectal tissues – latent MMP-2: 100% breast tumour
samples, 100% normal breast, 100% colorectal tumours and 92%
normal colorectal samples; latent MMP-9: 100% breast tumours,
93% normal breast, 100% colorectal tumours and 100% normal
colon samples (Table 1). However, the amounts of these enzymes
expressed were significantly greater in tumour tissue than the
corresponding normal tissue samples (Table 2; P < 0.05). The
major difference in MMP expression between tumour and normal
tissue was in the expression of active MMP-2 and active MMP-9
(Tables 1 and 2). Both the proportions of tissue samples expressing
these enzymes and the amounts of these active enzymes expressed,
were significantly greater in the tumour tissue in both breast and
colorectal samples (P < 0.05). Active MMP-2 was expressed by
98% breast tumours, 49% normal breast samples, 100% colorectal
tumours and 50% normal colon samples; active MMP-9 was
expressed by 78% breast tumours, 7% normal breast samples,
100% colorectal tumours and 13% normal colon samples. Figure 1
demonstrates representative gelatin zymograms for breast and
colorectal tissue samples.
MMP-3 expression
Following casein zymography, two different lysis bands were
observed, latent MMP-3 migrating at a molecular mass of 57
/59 kDa and active MMP-3 at 45 kDa. Both latent and active
MMP-3 were expressed in a significantly greater number of
colorectal and breast tumours when compared with the corre-
sponding normal tissue samples (P < 0.05, Table 1). Latent MMP-
3 was expressed in a greater proportion of breast tumours than
colorectal tumours (73% breast tumours compared to 56%
colorectal tissues) and active MMP-3 was expressed in a greater
proportion of colorectal tissue samples than breast (92% colorectal
tumour samples compared to 41% breast tumour samples; Table
1). Latent MMP-3 was more widely expressed in breast tissue than
active MMP-3; the opposite was seen with colorectal tissue, where
active MMP-3 was expressed in a greater proportion of tumour
and normal tissue samples than latent MMP-3 (Table 1).
MMP-1 expression
Of all the MMPs studied, MMP-1 was expressed the least by any
tissue and mainly only in the latent form. MMP-1 was expressed in
a greater proportion of tumour than normal tissue samples in both
tissues and was also significantly greater in colorectal tissue than
breast (P < 0.05). MMP-1 was only expressed in 22% breast
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Table 1 Expression of proteinases and inhibitors in breast and colorectal
samples: results are expressed as the percentage of samples expressing
each proteinase/inhibitor
Proteinase/ Breast Normal Colorectal Normal
inhibitor tumour (%) breast (%) tumour (%) colon (%)
Latent MMP-9 100 93 100 100
Active MMP-9 78 7 100 13
Latent MMP-2 100 100 100 92
Active MMP-2 98 49 100 50
Latent MMP-3 73 16 56 33
Active MMP-3 41 19 92 75
Latent MMP-1 22 0 74 32
Active MMP-1 12 0 9 5
uPA 90 56 100 77
TIMP-1 82 50 95 77
TIMP-2 100 80 100 80tumours and no normal breast tissue samples compared to 74%
colorectal tumours and 32% normal colon samples.
Plasminogen activator expression
Double substrate zymography determined PA activity within the
different tissue samples. Two PAs exist and they can be separated
electrophoretically according to their molecular mass, tPA
migrates at 70 kDa and uPA at 54 kDa. The only PA to be
expressed in any sample studied migrated at 54 kDa corre-
sponding to uPA. No lysis band was observed migrating at 70 kDa
in any tissue. uPA was expressed in a significantly greater propor-
tion of tumours than normal tissue samples in both breast and
colorectal cancer (P < 0.05); 90% breast tumours, 56% normal
breast samples, 100% colorectal tumour samples and 77% normal
colon samples (Table 1). uPA expression was greater in both
colorectal tissues than the equivalent breast tissue (Table 2),
however the difference was only significant when comparing
normal tissues (P < 0.05).
TIMP expression by Western blotting
Following Western blotting, TIMP-1 was expressed in a signifi-
cantly greater proportion of tumour tissue samples than normal
tissue in both breast and colorectal tissue (P < 0.05). TIMP-1 was
expressed by 82% breast tumour samples, 50% normal breast
samples, 95% colorectal tumour samples and 77% normal colon
samples studied. The amount of TIMP-1 expressed by the tumour
tissue was significantly greater in colorectal tissue than the breast
(P < 0.05) and in normal tissue, TIMP-1 expression was also greater
in colorectal tissue; however, the difference was not significant.
The proportion of tissue samples expressing TIMP-2 were the
same for both breast and colorectal tissue samples. Although
TIMP-2 expression in colorectal tissue was greater than that in
breast, the difference was not significant.
Total MMP activity
The rate of substrate hydrolysis (RSH) following quenched fluores-
cence substrate hydrolysis is proportional to the total amount of free
active MMPs present within the tissue samples. There was great
variation in the rates of substrate hydrolysis between both colorectal
and breast samples (Figure 2). All colorectal tissue samples success-
fully cleaved the substrate (i.e. RSH were greater than 0 pM min–1),
but not all breast samples exhibited substrate hydrolysis. However,
in both tissues the RSH was significantly greater in the tumour
tissue than the corresponding normal (P < 0.05).
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Table 2 Differences in proteinase and inhibitor expression and MMP activity in breast and colorectal tissue
Breast tumour Normal breast Colorectal tumour Normal colon
n = 43 n = 43 n = 24 n = 24
Latent 0–33.63 0–24.91 3.04–67.56 0.74–52.48
MMP-9 (10.52) (6.63) (26.9)a (20.6)a
Active 0–23.46 0–7.57 0.23–59.43 0–17.06
MMP-9 (11.56) (0) (18.8)a (0)
Total 0.088–70.62 0–24.68 3.27–126.79 0.74–58.87
MMP-9 (11.98) (7.14) (56.20) (21.98)
Latent 0.27–20.46 0.23–18.85 0.34–33.07 0–13.92
MMP-2 (5.74) (3.22) (7.3) (4.85)
Active 0–34.15 0–11.78 0.03–29.9 0–7.07
MMP-2 (5.29) (0) (8.3) (0.2)
Total 0.27–52.02 0.23–12.06 2.02–62.98 0–17.05
MMP-2 (8.3) (3.57) (15.04) (5.61)
Latent 0–9.2 0–3.7 0–52.08 0–23.58
MMP-3 (5.0) (0) (0.96) (0)
Active 0–27.7 0–17.6 0–69.08 0–69.74
MMP-3 (0) (0) (15.63)a (13.48)a
Total 0–31.4 0–17.6 0–121.16 0–82.11
MMP-3 (4.00) (0) (16.71)a (13.96)a
Latent 0–2.55 0 0–11.04 0–7.15
MMP-1 (0) (0) (2.5)a (0)
Active 0–3.31 0 0–8.2 0–5.5
MMP-1 (0) (0) (0) (0)
Total 0–5.86 0 0–17 0–16.5
MMP-1 (0) (0) (5.5)a (0)
uPA 0–56.00 0–16 0.86–21.49 0–18.34
(6.85) (1.45) (6.91) (3.55)a
TIMP-1 0–224.2 0–24.3 4.6–87.2 0–77.7
(6.00) (1.6) (15.3)a (4.15)
TIMP-2 3.1–36.5 0–26.4 4–15.4 0–3.1
(11.7) (7.7) (4.9) (1.5)
Rate of 0–8325 0–2245 791–22470 111.4–11 132.8
substrate hydrolysis (808.4) (225.1) (2207.5)a (978.45)a
Data are presented as the range and median values (in parentheses) for the amounts of each proteinase and inhibitor (in arbitrary units)
and the rate of substrate hydrolysis (pM min–1). aP < 0.05 Mann–Whitney U-test, colorectal versus breast tumour and normal colon versus
normal breast.The RSH was significantly greater in colorectal tissue than breast
tissue (P < 0.05) and this can be clearly observed with the range and
median values for the RSH (Table 2). For breast tumour tissue the
RSH ranged from 0 where samples exhibited no MMP activity
to 8325 pM min–1 and normal breast from 0 to 2245 pM min–1. The
median values were 808 and 225 pM min–1 respectively. However,
for colorectal tumour tissue, the range was from 791 to 22 470 pM
min–1 and for normal colorectal tissue from 111 to 11 133 pM min–1
with median values of 2207 and 978 pM min–1 respectively.
DISCUSSION
This study has examined proteolysis, one of the important
processes involved in tumour cell invasion and metastasis. Under
normal conditions, proteolytic enzymes are tightly controlled by
specific proteinase inhibitors; the MMPs are regulated by TIMPs
and PAs are regulated by PAIs. It is thought to be the balance
between these proteinases and inhibitors that determines the occur-
rence of proteolysis in vivo. If proteinase expression increases
and/or the inhibitor expression decreases then the balance prob-
ably favours proteolysis.
No single study described to date has compared proteolysis in
different cancers and few have studied proteinase and inhibitor
expression using more than one technique. In the present study,
proteolysis was compared in breast and colorectal cancer
employing three complementary techniques: zymography to deter-
mine proteinase expression, Western blotting to identify TIMPs
and quenched fluorescence substrate hydrolysis to determine the
total MMP activity within the samples.
Previously, studies have homogenized the tissue samples
(Ganesh et al, 1997; Parsons et al, 1998); however, in the present
study, the tissue was mechanically disaggregated, cells counted
and then lysed. The major advantage of this method is that the
same number of cells were present in each sample analysed rather
than using an equivalent weight of tissue as described in previous
studies. Therefore any differences observed in proteinase and
inhibitor expression between samples will be due to differences in
the relative proportions of cells, e.g. tumour cells compared to
stromal cells, and/or the tissue’s ability to produce, secrete or
activate these factors. Differences will not be due to cell numbers.
However, the disadvantage of using cell lysates compared to solid
tissue homogenates to determine proteinase expression, is that the
results are likely to be biased towards secreted proteinases,
e.g. MMP-9 and those that have cell surface receptors, e.g. MMP-
2 or uPA. It is unlikely that proteinases bound to the ECM,
e.g. tPA, will be identified by this method.
The present study described the presence of multiple proteinases
in normal and malignant breast and colorectal tissue. Furthermore,
differential proteinase profiles were observed in normal and
tumour tissue in both breast and colorectal samples. The expres-
sion of all proteinases identified (MMP-1, -2, -3, -9 and uPA) was
greater in tumours than normal tissue, in both breast and colorectal
samples. The expression of these proteinases also tended to be
greater in colorectal tissue than breast. The most marked differ-
ence in proteinase expression was observed following gelatin
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Figure 1 Gelatin zymograms illustrating the gelatinolytic activity of (A) two
paired breast tumour and normal tissue samples and (B) three colorectal
tumour samples and two normal colon samples. Lane 1 corresponds to the
molecular weight marker (mwm), the remaining lanes correspond to the
different tissue samples. All tumour samples (breast and colon) expressed
both the latent and active forms of MMP-2 and MMP-9. One normal breast
sample (Normal 1) expressed latent and active MMP-2 but no MMP-9. The
other normal samples (breast and colon, samples 2, 3 and 5) expressed
fainter bands corresponding to latent MMP-2 and MMP-9
Figure 2 Graph demonstrating the differences in the rate of substrate
hydrolysis (MMP activity) in breast and colorectal tumour and normal tissue
samples. The line corresponds to the median value for each tissue type. The
rate of substrate hydrolysis was significantly greater in tumour than normal
tissue samples in both breast (*P < 0.05, Mann–Whitney U-test) and
colorectal (**P < 0.05) tissue. The rate of substrate hydrolysis was
significantly greater in colorectal tissue than breast (***P < 0.05)zymography where the expression of the active forms of MMP-2
and MMP-9 were significantly greater in tumours when compared
to normal breast or colon. The number of colorectal and breast
samples expressing MMP-2 and -9 in the latent and active forms in
both tumour and normal tissue samples were similar for both
tissues. However, the amount expressed (latent, active and total)
was greater in colorectal tissue than in breast. Previously, two
independent studies using zymography determined comparable
mean values for MMP-2 and MMP-9 expression in colorectal and
breast cancer tissue, with MMP-9 expression being slightly higher
in the colon (Liabakk et al, 1996). Previous studies employing
gelatin zymography on breast (Brown et al, 1993; Davies et al,
1993; Remacle et al, 1998) and colorectal (Liabakk et al, 1996;
Parsons et al, 1998) cancer have demonstrated similar results for
MMP-2 expression to the present study. However, in contrast to
these studies, the present study identified active MMP-9 expres-
sion in a greater proportion of tumour samples (breast and
colorectal). Possible explanations for these discrepancies are the
disaggregation technique employed, the amount of tissue
collected, the grade of tumour and the area of the tumour from
which the tissue sample was taken.
Few studies have determined MMP-1 or MMP-3 expression in
either breast (Polette et al, 1993; Heppner et al, 1996; Remacle et
al, 1998) or colorectal cancer (Matrisian et al, 1994; Gallegos et al,
1995; Murray et al, 1996), and no study has compared the expres-
sion of these MMPs in both tissues. Latent MMP-3 alone was
expressed by a greater proportion of breast samples than colorectal.
However, the total amount of MMP-3 expressed (latent + active)
was greater in colorectal tissue. Active MMP-3 was expressed by a
greater proportion of colorectal tumour and normal tissue samples
than breast tissue samples. MMP-1 was the least expressed MMP.
MMP-1 expression was differential, with a greater proportion of
tumours expressing MMP-1 when compared to normal tissue
samples, and greater expression in colorectal versus breast. Few
studies investigating proteinase profiles in cancer have identified
MMP-1 expression. In breast cancer, the techniques previously
employed were immunohistochemistry (Clavel et al, 1992), ELISA
(Remacle et al, 1998) and Northern blotting (Polette et al, 1993)
and in agreement with the current study, MMP-1 expression was
low and not consistently observed. In colorectal cancer, two studies
have employed immunohistochemistry to determine MMP-1
expression, one study has shown an association between MMP-1
expression and poor prognosis (Murray et al, 1996); however, in
contrast another study observed no MMP-1 expression in colorectal
tumours (Gallegos et al, 1991).
The only PA detected in any tissue was uPA; however, the
absence of tPA may reflect the tissue disaggregation technique
employed in this study. The increased uPA expression in tumour
tissue is consistent with previous studies for both breast (Janicke
et al, 1992, 1993; Bouchet et al, 1994) and colorectal cancer
(Grondahl-Hansen et al, 1991; Pyke et al, 1991; Buo et al, 1995).
However, no previous study has compared PA expression in breast
and colorectal tissues. uPA expression in these studies was
confined to the stromal cells; however, the receptor for uPA,
uPAR, was expressed by tumour cells. tPA expression was also
observed in a few endothelial cells in both tumour and normal
tissue in one study (Grondahl-Hansen et al, 1991). There was also
variation in TIMP expression in breast and colorectal tissues as
determined by Western blotting. In both breast and colorectal
samples, TIMP-1 expression was greater in tumour than normal
tissue, but TIMP-1 expression was around threefold greater in both
colorectal tumour and normal tissue when compared to the equiv-
alent breast tissue. In contrast, TIMP-2 expression in tumour and
normal tissues was greater in breast than colorectal tissue, but
greater in tumour compared to normal for both tissues.
Both proteinase and inhibitor expression were found to be up-
regulated in tumour tissue in breast and colorectal cancer;
however, the most important determinant for proteolysis in vivo is
the balance between the expression and activation of proteinases
and the expression of their inhibitors. Quenched fluorescence
substrate hydrolysis determined the amount of free active MMPs
present within the tissue samples. This is indicative of proteolysis
occurring in vivo and has not been previously determined in either
breast or colorectal cancer. In both cancers the total MMP activity
was significantly greater in the tumour tissue and this may be rele-
vant in tumour invasion and metastasis. MMP activity was greater
in colorectal tumour and normal tissue than breast samples. The
active forms of MMP-2, -3 and -9 were all expressed in greater
amounts in colorectal tissue and will therefore contribute to the
increased activity. Normal colorectal tissue had a greater degree of
MMP activity (RSH) than either the breast tumour or normal
tissue. This suggests that the colon has a greater inherent rate of
tissue turnover than breast tissue (tumour and normal), or that
MMPs within the colon are involved in other physiological
processes, not just tissue remodelling. Another possible explana-
tion is that the colon may contain other MMPs not present in the
breast and not determined in this study.
In both breast and colorectal tumours, there was a wide variation
in the amounts of each proteinase and inhibitor expressed. A
possible explanation for this may be the varying amounts of stromal
components in the different tumours as some proteinases are
secreted by stromal cells, e.g. MMP-2 by fibroblasts. Therefore the
different proportions of each cell type present within each tumour
requires consideration. If the proteinases are only secreted when
active proteolysis occurs, then not all tumours will necessarily have
an increased proteinase expression at the time of resection.
Individual tumours within the same tissue type may rely on different
proteinases to degrade the ECM depending on the stage of progres-
sion, which may explain the wide variation observed in proteinase
expression. Another possible explanation is the differences in the
pathological stage/grade of each tumour. The grades of tumour were
known for 36/43 breast tumours studied; however, due to the small
colorectal sample numbers (n = 24) no attempt was made to corre-
late expression with the pathological stage in the present study. The
expression of MMP-2 and MMP-9 appeared to correlate with the
grade of breast tumour – grade 1 tumours had a lower expression
than grade 3, but an inverse correlation was observed with breast
tumour grade and MMP activity; the majority (20/36) of breast
tumours were grade 2 compared to grade 1 (6/36) and grade 3
tumours (10/36) (data not shown). The sample sizes for each grade
are not equivalent, making statistical comparisons inappropriate at
this stage. Therefore a greater number of both breast and colorectal
samples need to be analysed before firm conclusions can be deter-
mined between proteinase expression and tumour grade.
Although this study identified and quantified a number of
proteolytic enzymes that are present in the tumour environment and
potentially involved in tumour progression including MMPs and
serine proteinases, PAs, other enzymes have also been reported
to be involved in this process including MMP-7 and MMP-11
(Liabakk et al, 1996). As it is, the balance between activated
proteinases and their inhibitors that modulates tumour invasion,
measurements of these other enzymes may provide further
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metastasis. The tumour expression of these other MMPs are likely
to cleave the fluorescent substrate and this may explain the discrep-
ancies observed in proteinase expression in the present study.
In summary, the results presented here demonstrate increased
expression of some proteinases in tumour tissue when compared to
normal tissue from breast and colorectal cancers. This proteinase
expression as well as total MMP activity was greater in colorectal
tissue than breast, implying that individual proteinases have differ-
ential roles in both physiological and pathological processes in
different tissues.
The increased proteolysis observed in both colorectal and breast
tumour tissue may be important in invasion and metastasis, since
proteinases are involved at several stages of the metastatic cascade
including angiogenesis, local invasion, intravasation and extra-
vasation. For example, proteinase inhibitors have been used to try
and inhibit angiogenesis in an attempt to prevent and slow down
tumour progression (Taraboletti et al, 1995; Conway et al, 1996;
Stonelake et al, 1997; Yu et al, 1997). A better understanding of
the proteinases and inhibitors involved in tumour progression may
allow for therapeutic intervention at the earlier stages of tumour
progression.
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